Natera, Inc. (NASDAQ:NTRA) Chief Financial Officer, Michael Burkes Brophy, has recently engaged in transactions involving the company's common stock. The executive sold shares worth more than $82,000, according to a new regulatory filing.
The sale occurred on March 28, 2024, with Brophy selling 914 shares of Natera's common stock at a price of $90.4158 per share, totaling approximately $82,640. This transaction was part of a prearranged trading plan under Rule 10b5-1, which allows company insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information.
Additionally, the filing revealed that on March 27, 2024, Brophy acquired 2,292 shares of common stock. These shares were obtained through the vesting of Restricted Stock Units (RSUs) and did not involve any monetary transaction as per the footnotes in the filing. The RSUs are part of an award that vests over four years, with a quarter of the units having vested in March 2021 and the remainder vesting in equal quarterly installments.
Following the sale, Brophy's direct ownership in Natera stands at 72,024 shares of common stock. The transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission, which provides updates on the trading activities of a company's officers, directors, and other insiders.
Investors often monitor insider buying and selling as it can provide insights into an executive’s view of the company's future prospects. However, such transactions are not always indicative of a change in company performance and can be motivated by various factors, including personal financial management.
Natera, Inc. specializes in genetic testing and diagnostics with a focus on women’s health, oncology, and organ health. The company's shares are publicly traded on the NASDAQ stock exchange under the ticker symbol NTRA.
InvestingPro Insights
As Natera, Inc. (NASDAQ:NTRA) continues to navigate the market, recent transactions by CFO Michael Brophy have caught the eye of investors. To provide further context to these insider activities, let's delve into some real-time data and insights from InvestingPro.
Natera's market capitalization stands at a robust $11.23 billion, reflecting the company's significant presence in the genetic testing and diagnostics industry. Despite challenges in achieving profitability, with a negative Price-to-Earnings (P/E) ratio of -24.54 for the last twelve months as of Q4 2023, the company has demonstrated impressive revenue growth. The latest data reveals a year-over-year increase of 31.99% in revenue, hitting $1.08 billion.
InvestingPro Tips suggest that while analysts are optimistic about Natera's performance, revising earnings estimates upwards for the upcoming period, they do not expect the company to be profitable this year. Additionally, the stock's Relative Strength Index (RSI) indicates that it is currently in overbought territory, which could signal a potential pullback in the near term.
For those looking to dive deeper into Natera's financials and forecasts, InvestingPro offers a suite of additional tips. There are currently 13 more InvestingPro Tips available, which can help investors make more informed decisions. To explore these insights, visit https://www.investing.com/pro/NTRA and remember to use coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Keeping an eye on insider transactions like those of CFO Michael Brophy is just one piece of the puzzle. With the InvestingPro product, investors can gain a more comprehensive understanding of Natera's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.